MDM2 and melanoma: Our data suggest that the high p53 levels inducible in melanoma cells with an HDM2 antagonist may not result in programmed cell death in vitro or appreciable tumor regression in vivo unless the drug is administered in conjunction with a second agent that can facilitate these GSK-3β-dependent cytotoxic effects.